Meeder Advisory Services Inc. lifted its stake in Merck & Co., Inc. (NYSE:MRK – Free Report) by 7.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 67,679 shares of the company’s stock after buying an additional 4,891 shares during the period. Meeder Advisory Services Inc.’s holdings in Merck & Co., Inc. were worth $9,834,000 at the end of the most recent reporting period.
A number of other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. raised its position in Merck & Co., Inc. by 0.5% in the second quarter. BlackRock Inc. now owns 226,999,837 shares of the company’s stock worth $29,169,479,000 after purchasing an additional 1,073,507 shares in the last quarter. State Street Corp grew its stake in shares of Merck & Co., Inc. by 0.8% in the 3rd quarter. State Street Corp now owns 121,422,392 shares of the company’s stock valued at $17,745,131,000 after purchasing an additional 1,009,136 shares during the period. Wellington Management Group LLP raised its holdings in shares of Merck & Co., Inc. by 2.3% in the 2nd quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company’s stock worth $11,083,033,000 after buying an additional 1,934,312 shares in the last quarter. Fisher Asset Management LLC raised its holdings in shares of Merck & Co., Inc. by 8.3% in the 3rd quarter. Fisher Asset Management LLC now owns 41,699,432 shares of the company’s stock worth $6,059,345,000 after buying an additional 3,183,169 shares in the last quarter. Finally, Bank of America Corp DE lifted its position in shares of Merck & Co., Inc. by 10.5% during the 1st quarter. Bank of America Corp DE now owns 30,774,221 shares of the company’s stock worth $3,701,831,000 after buying an additional 2,919,780 shares during the period. 76.07% of the stock is owned by institutional investors and hedge funds.
Recent Merck & Co., Inc. Headlines
Investors following MRK have been watching these headlines:
- Positive Sentiment: Merck said its TroFuse-015 trial of sac-TMT met its primary overall-survival endpoint in patients with advanced gastroesophageal adenocarcinoma who had received at least two prior lines of treatment. The result adds encouraging evidence for a potential oncology product. Reuters: Merck's drug prolongs survival in advanced stomach, esophageal cancers in trial
- Positive Sentiment: A German court overturned an injunction that had restricted Merck from distributing and offering Keytruda SC in Germany. The ruling removes an immediate obstacle to the formulation, although Halozyme says it will pursue a new patent lawsuit. Zacks: HALO Faces Legal Setback in Germany Over MRK's Keytruda SC
- Negative Sentiment: Merck has stopped development of nemtabrutinib and ended its Phase 3 BELLWAVE studies after concluding the drug’s benefit-risk profile did not justify continuing. This removes a late-stage blood-cancer candidate from its pipeline. Yahoo Finance: What Does Merck Losing Nemtabrutinib Mean For Its Blood Cancer Pipeline?
Insider Activity at Merck & Co., Inc.
In other Merck & Co., Inc. news, EVP Richard Deluca sold 58,185 shares of the firm’s stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $148.01, for a total transaction of $8,611,961.85. Following the transaction, the executive vice president owned 112,955 shares in the company, valued at approximately $16,718,469.55. This trade represents a 34.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.17% of the stock is currently owned by company insiders.
Wall Street Analysts Forecast Growth
MRK has been the subject of several analyst reports. UBS Group lifted their price target on shares of Merck & Co., Inc. from $145.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, August 20th. Argus assumed coverage on shares of Merck & Co., Inc. in a report on Tuesday, November 3rd. They set a “strong-buy” rating for the company. Daiwa Securities Group raised Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 target price on the stock in a report on Wednesday, August 12th. Freedom Broker increased their price target on Merck & Co., Inc. from $125.00 to $140.00 and gave the stock a “hold” rating in a research report on Monday, November 2nd. Finally, Scotiabank raised their price target on Merck & Co., Inc. from $155.00 to $180.00 and gave the company a “sector outperform” rating in a report on Tuesday, September 29th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and twelve have issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $155.74.
Read Our Latest Research Report on Merck & Co., Inc.
Merck & Co., Inc. Price Performance
Shares of MRK stock opened at $133.56 on Friday. The firm has a market cap of $329.26 billion, a price-to-earnings ratio of 137.69, a PEG ratio of 6.13 and a beta of 0.13. Merck & Co., Inc. has a 12 month low of $95.36 and a 12 month high of $156.92. The company has a quick ratio of 1.14, a current ratio of 1.35 and a debt-to-equity ratio of 1.11. The stock has a 50-day moving average price of $145.28 and a 200 day moving average price of $129.29.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last issued its earnings results on Thursday, October 29th. The company reported $2.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.09 by $0.40. Merck & Co., Inc. had a net margin of 3.64% and a return on equity of 16.73%. The company had revenue of $18.09 billion for the quarter, compared to analyst estimates of $17.33 billion. During the same quarter last year, the firm earned $2.58 EPS. The company’s revenue for the quarter was up 4.7% on a year-over-year basis. Research analysts expect that Merck & Co., Inc. will post 2.83 EPS for the current year.
Merck & Co., Inc. Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 8th. Investors of record on Tuesday, December 15th will be paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 2.6%. This is a boost from Merck & Co., Inc.’s previous quarterly dividend of $0.85. The ex-dividend date of this dividend is Tuesday, December 15th. Merck & Co., Inc.’s payout ratio is presently 350.52%.
Merck & Co., Inc. Company Profile
Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.
See Also
- Five stocks we like better than Merck & Co., Inc.
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
